Alector announces planned departure of President/COO and CMO; appoints interim CMO

Alector, Inc.

Shehnaaz Suliman (President/COO) to step down; transition through Dec 31, 2021, then advisor.
Robert Paul (CMO) steps down; will work part-time ($1,730/week) until Oct 31 health benefits, then advisor.
Sam Jackson, SVP Clinical Sciences, appointed interim CMO effective Sept 7, 2021.
Both executives will remain as advisors until end of 2021.
Dr. Suliman joined 2019, Dr. Paul 2016; transitions are voluntary.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Shehnaaz Suliman

President and Chief Operating Officer

ALEC · Alector, Inc.

Effective: 2021-12-31
Filed: September 7, 2021, 7:59 PM ET

On September 7, 2021, Alector, LLC, a subsidiary of Alector, Inc. (collectively, the “Company”) entered into an agreement (the “Transition Agreement”) with Shehnaaz Suliman, the Company’s President and Chief Operating Officer, setting forth the terms of Dr. Suliman’s voluntary transition from the Company.

Departed

Robert Paul

Chief Medical Officer

ALEC · Alector, Inc.

Effective: 2021-12-31
Filed: September 7, 2021, 7:59 PM ET

on September 7, 2021, the Company entered into a letter agreement (the “Letter Agreement”) with Robert Paul, the Company’s Chief Medical Officer, setting forth the terms of Dr. Paul’s voluntary transition from the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Shehnaaz Suliman changed role as President and Chief Operating Officer at Alector, Inc..

Action: transition
Role: President and Chief Operating Officer

Exact text from the filing

On September 7, 2021, Alector, LLC, a subsidiary of Alector, Inc. (collectively, the “Company”) entered into an agreement (the “Transition Agreement”) with Shehnaaz Suliman, the Company’s President and Chief Operating Officer, setting forth the terms of Dr. Suliman’s voluntary transition from the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Paul changed role as Chief Medical Officer at Alector, Inc..

Action: transition
Role: Chief Medical Officer

Exact text from the filing

on September 7, 2021, the Company entered into a letter agreement (the “Letter Agreement”) with Robert Paul, the Company’s Chief Medical Officer, setting forth the terms of Dr. Paul’s voluntary transition from the Company.

View on SEC.gov

Alector, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-266663

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.